aemd stock: Aethlon Medical (AEMD) Overview

Aethlon Medical, Inc. (AEMD)

This article covers aemd stock — the publicly traded common shares of Aethlon Medical, Inc. — explaining the company profile, principal technologies, clinical and regulatory status, financial and market characteristics, investor resources, and risks. If you are researching aemd stock as a retail investor, student, or industry observer, this guide summarizes primary information sources and what to watch next.

截至 2026-01-28，据 Yahoo Finance 报道：请参阅原始报价页以获取最新市值与成交量数据。

As of January 28, 2026, according to publicly listed financial pages and the company investor relations site, Aethlon Medical is a small-cap medical device/therapeutics company focused on blood-purification technology, principally the Hemopurifier. This article does not offer investment advice; it is informational and cites where to confirm time-sensitive figures.

Company Overview

Aethlon Medical, Inc. (traded as aemd stock) is a clinical-stage medical device company focused on developing and commercializing blood-purification technologies intended to remove viruses, exosomes, and other pathogenic particles from the circulation. The company’s mission emphasizes adjunctive therapies for infectious disease and oncology-supportive care.

Headquartered in the United States, Aethlon Medical was founded in the late 1990s/early 2000s and operates with a small employee base typical of clinical-stage microcap companies. The company relies primarily on research and development, clinical collaborations, contract manufacturers, and grant or investor financing to advance product development.

Note: specific employee counts, exact headquarter address, and corporate phone numbers change with filings and the company website; consult the company’s investor relations page for current contact details.

History

A chronological summary of major milestones for aemd stock and Aethlon Medical provides context for the company’s progress:

• Founding and early development: Aethlon Medical originated from research into lectin-based capture technologies intended to bind and remove glycosylated particles such as certain viruses and tumor-derived exosomes.

• Product concept and initial prototypes: The company developed the Hemopurifier concept and proceeded through preclinical testing to demonstrate the binding and removal of targeted particles in ex vivo and animal models.

• Clinical program launches: Aethlon has pursued pilot clinical studies and compassionate use in severe infectious disease settings, and planned early-stage trials for oncology-supportive applications.

• Corporate financing and microcap listing: Over time, Aethlon has raised capital through private placements and registered offerings, resulting in publicly traded common stock (aemd stock) listed on U.S. public markets. Dilutive financings, warrants, and registered offerings are a recurring feature typical for companies at this stage.

• Recent strategic actions: The company has engaged in international clinical activities, research collaborations, and regulatory interactions to support next-stage trials for the Hemopurifier.

This timeline is a high-level summary. For detailed milestone dates and offering histories, consult SEC filings, company press releases, and the investor relations archive.

Products and Technology

Aethlon Medical’s value proposition centers on targeted, extracorporeal blood-purification devices intended to remove pathogenic particles from circulation. The company’s primary technology platform underlies the Hemopurifier and related consumables.

Hemopurifier

The Hemopurifier is Aethlon’s lead product candidate. It is an extracorporeal cartridge designed to filter blood through affinity media that selectively bind glycosylated viral particles and tumor-derived exosomes.

Mechanism of action:

• Lectin-based capture: The Hemopurifier uses lectin or similar affinity ligands that recognize specific sugar moieties on the surface of viruses and certain extracellular vesicles (exosomes).
• Extracorporeal removal: Patient blood is circulated through the device using conventional vascular access and extracorporeal blood-pump systems; the cartridge captures target particles while returning treated blood to the patient.
• Intended adjunctive use: The device is generally described as an adjunctive therapy to reduce circulating viral load or remove immunosuppressive exosomes in oncology settings — not as a standalone cure.

Claimed clinical applications and significance:

• Antiviral support: Aimed at severe viral infections where reducing circulating infectious particles may aid clinical outcomes.
• Oncology supportive care: Removing tumor-derived exosomes is proposed to reduce immunosuppression and potentially enhance responses to immunotherapy, though these indications remain investigational.

The Hemopurifier’s platform nature means different cartridge configurations or protocols could be investigated for distinct clinical applications. The technology’s differentiation rests on affinity-based capture versus other blood-purification modalities such as dialysis, adsorption-based hemoperfusion, or plasma exchange.

Research, Clinical Trials, and Regulatory Status

Aethlon Medical has advanced preclinical validation and early clinical evaluations for the Hemopurifier. Clinical trial activity has included pilot studies, compassionate use case reports, and planned formal trials in multiple jurisdictions.

• Trial locations and scope: Public information has referenced clinical activity or planned studies in regions including the United States, India, and Australia, with protocols focused on safety, feasibility, and proof-of-concept endpoints.

• Major trial results and milestones: The company has published or announced compassionate-use case outcomes and early clinical observations. While some individual case reports suggested reduction in circulating targets following treatment, robust randomized controlled data are limited and ongoing trial designs aim to provide clearer evidence.

• Regulatory designations: At times, device developers pursue expedited pathways or special device designations (such as Breakthrough Device designation in the U.S.). If and when Aethlon receives any formal regulatory designation, the company will announce it via press release and corresponding regulatory records. Always verify current regulatory status using official agency databases and the company’s filings.

As of January 28, 2026, according to company releases and public trial registries, Aethlon continues to plan and recruit for clinical programs targeting specific infectious and oncology-related indications. Confirm up-to-date trial enrollment and status on clinical registry websites and the company’s investor updates.

Market and Competitive Landscape

Aethlon operates in a competitive field that spans blood-purification devices, extracorporeal therapies, and supportive oncology technologies. Key competitive categories include:

• Hemoperfusion and adsorption devices: Commercial devices intended for toxin or cytokine removal in critical care.
• Therapeutic plasma exchange (TPE) and apheresis technologies: Procedures that remove plasma constituents broadly, used in autoimmune and certain hematologic conditions.
• Adjunctive antiviral or immunomodulatory therapies: Pharmaceutical antivirals, monoclonal antibodies, and immunotherapies used to treat infections or mitigate tumor immunosuppression.

Differentiating factors for Aethlon and the Hemopurifier:

• Target specificity: The Hemopurifier’s lectin-based approach is intended to bind glycosylated particles selectively, distinguishing it from nonspecific adsorption.
• Platform flexibility: The cartridge approach could be adapted for different targets and indications.

Competitive risks include established medical-device companies with larger development budgets, clinicians’ adoption hurdles, and the need for robust clinical evidence to justify use and reimbursement.

Financial Information

Aethlon Medical is a clinical-stage company. Typical financial characteristics for aemd stock and similar companies include limited or no product revenue, persistent operating losses due to R&D and clinical costs, and dependence on financing to fund operations.

• Revenue sources: At this stage, revenue (if any) may come from limited product sales, service agreements, grant funding, or early access programs. The predominant expenditures are research, clinical trials, regulatory activities, and general corporate costs.

• Cash position and runway: Cash-on-hand and the company’s burn rate determine its runway. Companies like Aethlon typically raise capital via registered offerings, private placements, or at-the-market programs to finance continued development.

• Debt: Clinical-stage microcaps often have minimal long-term debt but may use convertible instruments, warrants, and similar capital-raising tools.

All financial data are time-sensitive. For current figures such as cash balance, net loss, and revenue, consult the company’s most recent SEC filings (10-K, 10-Q) and investor presentations.

Key Financials and Filings

Investors tracking aemd stock typically monitor the following filings and metrics:

• SEC filings: Annual reports (10-K), quarterly reports (10-Q), current reports (8-K), and registration statements.
• Cash on hand: Available liquidity from the balance sheet.
• Net loss and operating expenses: Quarterly and annual trends in R&D and G&A spending.
• Shares outstanding and market capitalization: Diluted share counts after accounting for warrants and convertible instruments.
• Recent offerings: Prospectuses and press releases describing registered offerings or financing terms.

Primary sources for these documents include the SEC’s EDGAR system and the company’s investor relations page.

Stock Information

AEMD is the common stock ticker for Aethlon Medical; in public market listings and real-time data feeds this security appears with that symbol. AEMD is generally categorized as a microcap or penny stock, which implies lower market capitalization and heightened trading volatility compared with larger-cap securities.

• Exchange and trading: AEMD trades on U.S. public markets (refer to current quote providers for exchange designation). For investors interested in trading aemd stock, trading services and brokers (including Bitget’s stock services where available) provide live quotes and execution; check availability in your jurisdiction.

• Trading characteristics: As a microcap/penny-stock, aemd stock commonly experiences lower average daily volume, wider bid-ask spreads, and price volatility. These characteristics impact liquidity and execution quality.

Market Data and Price History

Market data elements investors commonly track for aemd stock include the 52-week high/low, market capitalization band, average volume, and historical volatility. These metrics change daily and should be verified on financial quote pages and the company’s filings.

As of January 28, 2026, according to published financial quote pages and market data aggregators, market metrics for AEMD are available on platforms such as Yahoo Finance, Google Finance, Morningstar, and other quotation services. Consult those pages to obtain exact, current numeric values for market cap, 52-week range, and average volume.

Capital Raises, Dilution, and Corporate Actions

Capital raises are a notable driver of share count changes for aemd stock. Typical corporate actions affecting shareholders include:

• Registered offerings and private placements: Sales of common stock, preferred stock, and units that may include warrants.
• Issuance of warrants and convertible instruments: Potentially dilutive if exercised or converted.
• Reverse stock splits or forward splits: Employed sometimes to meet listing requirements or manage per-share price levels.

Investors should read the company’s prospectuses and registration statements to understand dilution terms, exercise prices for warrants, and anticipated use of proceeds.

Corporate Governance and Management

Aethlon’s governance follows standard corporate structures: a board of directors, executive officers (CEO, CFO, and others), and governance committees as appropriate for a publicly reporting company. Short executive bios are typically available in proxy statements and on the investor relations site.

Key governance resources:

• Proxy statements: Provide director biographies, executive compensation, and governance matters.
• Board composition: Size, independence, and committee assignments.

For current executive names, titles, and brief bios, consult the company’s investor relations materials. These materials are periodically updated after executive changes.

Investor Relations

Investor relations is the primary channel for shareholder communications. Typical IR information for aemd stock includes:

• Company investor relations contact details: phone, email, and mailing address listed on the IR page.
• Transfer agent details: Name and contact information for the transfer agent that manages shareholder records.
• Official channels: Press releases, SEC filings, investor presentations, and recorded conference calls/webcasts.

When researching aemd stock, rely on the company’s IR page and SEC filings for authoritative disclosures and to access historical press releases.

Risks and Considerations for Investors

Investing in a clinical-stage microcap like aemd stock carries distinct risks. Summarized, these include:

• Clinical and regulatory risk: The Hemopurifier’s future depends on the outcome of clinical trials, regulatory clearances, and demonstration of clinical benefit.
• Technology and execution risk: Translating early-stage or pilot results into scalable manufacturing, robust clinical protocols, and commercial adoption is challenging.
• Financial risk and dilution: Dependence on external financing can lead to dilution from equity offerings, convertible securities, and warrants.
• Liquidity and market risk: Low trading volume and wide bid-ask spreads increase transaction costs and price volatility.
• Competitive and reimbursement risk: Even with regulatory clearance, obtaining clinician adoption and payment/reimbursement can be uncertain.

This list is not exhaustive. Investors and observers should perform due diligence using primary filings and consult qualified advisors for investment decisions.

Trading and Analyst Coverage

aemd stock typically shows more retail investor interest relative to institutional coverage. Social platforms and microcap forums may host active discussions; one noted community feed historically referenced by market participants is StockTwits. Professional analyst coverage for microcap clinical-stage device companies may be limited; coverage levels vary over time.

Retail vs. institutional interest:

• Retail: Retail traders and small investors often drive volume spikes in microcaps; social media sentiment can influence short-term price moves.
• Institutional: Institutional involvement is often limited until a company demonstrates clearer clinical or commercial milestones.

Price targets and formal analyst reports may be sparse. Follow mainstream financial outlets and specialized medical-device research firms for any emerging coverage.

Legal, Regulatory, and Public Affairs

Investors should monitor for material regulatory notices, enforcement actions, or litigation that could materially affect aemd stock. Typical sources for such updates are company 8-K disclosures, SEC filings, and official regulatory agency announcements.

If material litigation or enforcement exists, it will be disclosed in periodic filings and press releases. No speculation or unverified claims are included here; confirm current legal or regulatory status via primary documents.

See Also

• Listed microcap medical-device companies
• Clinical-stage biotech and device company investing
• Medical device regulatory pathways (including expedited pathways where applicable)

References

Primary public sources to consult for authoritative data on aemd stock include (reference names only — consult original pages for live data):

• Aethlon Medical — Investor Relations page (company disclosures and press releases)
• Yahoo Finance — AEMD quote and market data
• Seeking Alpha — AEMD company profile and commentary
• StockTwits — AEMD community feed
• Google Finance — AEMD market page
• Morningstar — AEMD quote and analysis
• CNBC, Barchart, and CNN Markets — market pages and news summaries

截至 2026-01-28，据 seeking alpha、yahoo finance 与公司投资者页面披露，请以这些来源的当日数据为准。

External Links

For live market quotes, SEC filings, and company filings, consult the following sources directly (use the site search or the company name/ticker to find pages):

• Aethlon Medical official investor relations page
• SEC EDGAR filings for Aethlon Medical
• Major finance pages providing quotes and historical market data (e.g., Yahoo Finance, Google Finance, Morningstar)

Note: external URLs are intentionally not embedded here. Use your browser or financial platform to access these pages.

Notes for Editors and Readers

• Time-sensitive data: Market data (market cap, daily volume, 52-week high/low) and clinical trial status are time-sensitive and should be updated frequently with citations to the company’s press releases, SEC filings, and clinical-trial registries.
• Sources: The material in this article is compiled from publicly available investor pages, financial-quote services, and company disclosures. For regulatory designations and formal trial outcomes, consult official agency resources and peer-reviewed publications where available.
• Tone and use: This article is informational and neutral; it does not provide investment advice.

How to Follow aemd stock (Practical Steps)

1. Start with the company investor relations page for press releases and presentation materials.
2. Check SEC EDGAR for the latest 10-Q, 10-K, and 8-K filings to verify financials and material events.
3. Monitor clinical registry entries for active trial status and enrollment updates.
4. Use major market-quote services for live price, 52-week range, market cap, and average volume.
5. Track social and investor community channels (e.g., community feeds) for sentiment, but verify claims with primary filings.
6. For trading, review available brokerages and platforms — Bitget offers multi-asset services and wallet tools; verify whether stock trading for aemd stock is available in your jurisdiction and under your account terms.

What to Watch Next for aemd stock

• Clinical milestones: Enrollment completion, interim analyses, or randomized trial results for Hemopurifier indications.
• Regulatory interactions: Any granted designations, IDE approvals, or clearance/approval decisions.
• Financing events: Announced registered offerings or private placements that could affect shares outstanding.
• Partnerships and commercial agreements: Any manufacturing, distribution, or co-development deals which could change commercialization prospects.

Further exploration: To stay current, subscribe to the company’s official investor communications and set alerts on major financial pages for ticker AEMD.

Final Notes and Action Steps

If you want to track aemd stock more actively:

• Visit the company investor relations page and SEC filings for primary documentation.
• Use a trusted market data provider for real-time quotes and historical charts.
• For trading and custody, check whether your broker or Bitget’s services support trading AEMD in your jurisdiction.

Explore more Bitget features to manage multi-asset portfolios and consider Bitget Wallet for custody solutions where applicable. Always verify availability, fees, and local regulatory permissions before trading.

Thank you for reading this aemd stock overview. For the latest market metrics and filings, consult the referenced sources directly and monitor company announcements.